科研之友
微信
新浪微博
Facebook
分享链接
摘要
The 2014 version of the NCCN Guidelines for Melanoma lists 6 preferred regimens, most with a category 1 recommendation, and 8 "other active regimens." Effective new agents include ipilimumab, a monoclonal anti-CTLA4 antibody, and agents targeted against mutated BRAF and MEK. Researchers are now focused on the optimal way to combine or sequence these agents, while exploring other new classes.
- 出版日期2014-5
